On April 5, 2023 Nerviano Medical Sciences Srl,a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, reported that two posters will be presented at the upcoming AACR (Free AACR Whitepaper) annual meeting which will be held April 14-19, 2023 at the Orange County Convention Center, Orlando, Florida (Press release, Nerviano Medical Sciences, APR 5, 2023, View Source [SID1234629833]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster #: 1615. Title: NMS-812, a novel potent PERK inhibitor that also inhibits GCN2, exhibits strong anti-tumor activity as single agent and in combination in preclinical models. Presenter: Claudia Perrera, PhD, Head of Discovery Pharmacology, Nerviano Medical Sciences. Session: PO.ET09.03 – Novel Antitumor Agents 3. When: Monday, April 17 9.00 AM-12.30 PM ET. Where: Section 17 of the Exhibition Hall.

Poster #: 4036. Title: NMS-0963 is a novel potent, selective and orally available Syk inhibitor with promising preclinical activity in diffuse large B-cell lymphoma. Presenter: Grazia Saturno, PhD, Global Asset Leader, Nerviano Medical Sciences. Session: PO.ET09.08 – Tyrosine Kinase and Phosphatase Inhibitors 2. When: Tuesday, April 18 9.00 AM-12.30 PM ET. Where: Section 21 of the Exhibition Hall.

About NMS-812
NMS-812 is a potent and selective inhibitor of PERK and GCN2, two key kinases involved in regulating the "integrated stress response" (ISR), a series of signaling pathways that facilitate cellular adaptation to various types of stress conditions and which, importantly, include those commonly encountered by tumor cells. In this presentation, we elucidate key preclinical data which led to selection of NMS-812 as a clinical candidate. NMS-812 has the potential to be a first-in-class agent targeting the ISR and started patient enrolment in a FIH clinical trial in the setting of relapsed/refractory multiple myeloma in mid-2022 (NCT05027594).

About NMS-0963
NMS-0963 is a novel potent, selective and orally available Syk (Spleen tyrosine kinase) inhibitor. Syk is a non-receptor cytoplasmic tyrosine kinase that plays a fundamental role in BCR (B-Cell Receptor) signaling. Syk represents a therapeutic target for the inhibition of the BCR pathway in B-Cell malignancies, such as Diffuse Large B-Cell Lymphoma (DLBCL), which depend on BCR signaling for aberrant proliferation and growth. In this poster, we present the discovery and characterization of NMS-0963 including in vitro biochemical profile, cell proliferation/mechanism of action and in vivo pharmacodynamic and efficacy data which support the rationale for clinical development of NMS-0963 in DLBCL.

Link:20230404-PERK and SYK posters AACR (Free AACR Whitepaper)2023_PressRelease

On March 31, 2023, Enzo Biochem, Inc. (the "Company") entered into a Revolving Loan and Security Agreement (the "Credit Facility") among Enzo Clinical Labs, Inc. and Enzo Life Sciences, Inc., as borrowers (the "Borrowers"), the Company and certain of its domestic subsidiaries, as guarantors (the "Guarantors"), and Gemino Healthcare Finance, LLC d/b/a SLR Healthcare ABL as lender (Filing, 8-K, Enzo Biochem, APR 5, 2023, View Source [SID1234629834]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Credit Facility provides for a maximum $8 million revolving line of credit. The Borrowers intend to use the borrowing proceeds under the Credit Facility for working capital and general corporate purposes. The commitment under the Credit Facility will expire after one year and all outstanding borrowings under the Credit Facility will become due and payable at that time. Prior to its expiration, the Borrowers will prepay and terminate the Credit Facility upon closing of the Asset Purchase Agreement pertaining to the Clinical Labs business, and a standard termination fee will be payable.

The Credit Facility is secured by a first priority perfected security interest in the collateral. The collateral includes substantially all the U.S. assets of the Borrowers and the Guarantors, including among other assets, cash, receivables, inventory and fixed assets.

Borrowings under the Credit Facility, which are based on eligible receivables of the Borrowers’ Clinical Labs and U.S.-based Life Sciences operating segments, accrue interest at the rate per annum equal to Term SOFR (Secured Overnight Financing Rate) for a three-month tenor plus 5.50%. Other fees, such as an unused line fee and a collateral monitoring fee, also apply. The Borrowers borrowed $5.5 million under the Credit Facility upon the closing thereof.

The Credit Facility includes customary affirmative and negative covenants for revolving credit facilities of this nature, including certain limitations on the incurrence of additional indebtedness and liens. In addition, the Credit Facility requires the Borrowers to maintain certain minimum liquidity levels as of the last day of each calendar month. The levels decline over time, starting at $4 million as of April 30, 2023, then $3 million as of May 31, 2023 and $2 million as of the end of each month thereafter.

The Credit Facility includes customary events of default for revolving credit facilities of this nature, including failure to pay outstanding principal or interest, failure of applicable representations or warranties to be correct in any material respects, failure to perform any other term, covenant or agreement, certain defaults upon obligations under the Employee Retirement Income Security Act, bankruptcy or a change in control. Such events of default would require the repayment of any outstanding borrowings and the termination of the right to borrow additional funds under the Credit Facility.

The description above is only a summary of the material provisions of the Credit Facility and is qualified in its entirety by reference to a copy of the Credit Facility, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated by reference herein.

On April 5, 2023 CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, reported that Tanya Urbach, Board Chair, Cyrus Arman, President, Antonio Migliarese, Chief Financial Officer, and Scott Hansen, our newly appointed Head of Research and Basic Science, will host an investment community webcast to provide a Company update on Tuesday, April 11, 2023 (Press release, CytoDyn, APR 5, 2023, View Source [SID1234629831]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Following the update, questions submitted prior to the webcast as directed below will be addressed to the extent appropriate.

Date: Tuesday, April 11, 2023
Time: 1:00 pm PT / 4:00 pm ET
Access: View Source
Questions: Please submit any questions prior to the webcast, and not later than Noon PT, Friday, April 7, 2023. Questions can be submitted via email to: [email protected]. Per CytoDyn’s current policy, the presenters will not be able to take live questions during the webcast.
This is a livestream presentation. Participants are encouraged to login early prior to the start of the event. The replay will be available approximately 60 minutes after the conclusion of the webcast and can be accessed via the above link until May 11, 2023.

On April 5, 2023 Corcept Therapeutics Incorporated (Nasdaq: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol, reported the final results of its previously announced tender offer to purchase up to 7,500,000 shares of its common stock, par value $0.001 per share, at a price not greater than $22.00 nor less than $19.25 per share, in cash, less any applicable withholding taxes and without interest (the "Tender Offer"), which expired one minute after 11:59 p.m., New York City time, on March 31, 2023 (Press release, Corcept Therapeutics, APR 5, 2023, https://ir.corcept.com/news-releases/news-release-details/corcept-therapeutics-announces-final-results-tender-offer [SID1234629830]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Based on the final count by Continental Stock Transfer & Trust Company, the depositary for the Tender Offer (the "Depositary"), 6,610,369 shares of Corcept’s common stock were validly tendered and not properly withdrawn at or below a purchase price of $22.00 per share.

In accordance with the terms and conditions of the Tender Offer, based on the final count, Corcept has accepted for purchase 6,610,369 shares of common stock at a purchase price of $22.00 per share, for an aggregate cost of $145,428,118, excluding fees, any excise taxes and expenses relating to the Tender Offer. The number of shares that Corcept has accepted for purchase in the Tender Offer represents approximately 6 percent of the total number of shares of common stock outstanding as of March 31, 2023. Corcept had 101,545,296 shares of common stock outstanding following payment for the shares of common stock purchased in the Tender Offer.

The Depositary will promptly pay for all of the shares of common stock accepted for purchase in accordance with the terms and conditions of the Tender Offer.

The sole dealer manager for the Tender Offer is Piper Sandler & Co. D.F. King & Co., Inc. is serving as the information agent for the Tender Offer and Continental Stock Transfer & Trust Company is serving as the depositary. For all questions relating to the Tender Offer, please contact the information agent, D.F. King & Co., Inc. at [email protected] or call toll-free at 1 (800) 821-8781, or call the dealer manager, Piper Sandler & Co. at (312) 267-5100.

On April 5, 2023 Champions Oncology, Inc. (CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, reported that its Board of Directors has approved a share repurchase program with authorization to purchase up to $5 million of its common stock through April 30, 2024 pursuant to Rule 10b-18 of the Securities Exchange Act of 1934 (Press release, Champions Oncology, APR 5, 2023, View Source [SID1234629829]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Ronnie Morris, CEO of Champions commented, "We are committed to strategically deploying capital to drive long-term value for stockholders. We believe that the current macroeconomic environment along with the long-term prospects of our business provide a unique buyback opportunity. The stock repurchase program reflects our confidence in the execution of our strategic priorities and the bright future of the business".

David Miller, CFO of Champions added, "We believe the strength of our balance sheet and the current valuation, present an attractive and strategic buying opportunity for our stock. The plan reflects the confidence we have in our business and our strategy to invest for long-term growth, which we believe is not reflected in the current market valuation. We will continue to monitor the program in light of changes we see in our business, the capital markets and the economy in general."

Under the stock repurchase program, Champions expects to repurchase shares of its common stock from time to time in open market transactions as permitted under applicable rules and regulations. The number, price, structure, and timing of the repurchases, if any, will be evaluated by the Company depending on market conditions, liquidity needs, and other factors. The repurchase authorization does not oblige the Company to acquire any particular amount of its common stock. The Board of Directors may suspend, modify, or terminate the stock repurchase program at any time without prior notice.